Navigation Links
QRxPharma Announces Interim Analysis of Final Pivotal Phase 3 Study for MoxDuo®IR
Date:9/1/2010

analgesic effects of flexible dose versus fixed low dose of MoxDuo IR over a 48 hour study period. Since the blinded interim analysis was based on how much variability was observed when both dosage groups were combined and did not evaluate the magnitude of the difference between the two treatment groups per se, one must be cautious in drawing conclusions that the expected endpoints will be met. This type of interim analysis conducted for the purpose of sample size re-estimation, which was accepted by the FDA, does not result in a statistical penalty in the p-values of the final analysis to be conducted upon study completion.For more information please contact:Dr John W HoladayManaging Director and Chief Executive OfficerTel: +1 301 908 3086Email: john.holaday@qrxpharma.comChris J CampbellChief Financial Officer and Company SecretaryTel: +61 2 9492 8021Email: chris.campbell@qrxpharma.comForward Looking StatementsThis release contains forward-looking statements. Forward-looking statements are statements that are not historical facts; they include statements about our beliefs and expectations. Any statement in this release that states our intentions, beliefs, expectations or predictions (and the assumptions underlying them) is a forward-looking statement. These statements are based on plans, estimates and projections as they are currently available to the management of QRxPharma. Forward-looking statements therefore speak only as of the date they are made, and we undertake no obligation to update publicly any of them in light of new information or future events. By their very nature, forward-looking statements involve risks and uncertainties. A number of important factors could therefore cause actual results to differ materially from those contained in any forward-looking statement. Such factors include risks relating to the stage of products under development; uncertainti
'/>"/>
SOURCE QRXPharma
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. QRxPharma Doses First Patients in Phase III Clinical Trial Program for its Dual Opioid Pain Therapy
2. QRxPharma Releases Successful Phase 3 Study Results for Dual Opioid Pain Therapy
3. QRxPharma Releases Additional Phase 3 Data for Q8003IR Dual Opioid Pain Therapy
4. QRxPharma Successfully Completes Comparative Study for Dual-Opioid(TM) Pain Therapy
5. QRxPharma Inks Deal with Patheon for the Manufacture of MoxDuo(TM)CR
6. QRxPharma Limited Announces A$21.6 Million Fully Underwritten Capital Raising
7. QRxPharma Initiates Second Pivotal Phase 3 Study of MoxDuo(TM)IR Dual-Opioid(TM) for NDA Submission
8. QRxPharma Limited and China Aoxing Pharmaceutical Company Announce Strategic Alliance for Development of MoxDuo(R)IV
9. QRxPharma Releases Additional Pivotal Phase 3 Combination Rule Study Data for MoxDuo(R)IR in Patients with Post-Surgical Pain
10. QRxPharma Successfully Completes Comparative Phase 1 Proof-of-Concept Study for MoxDuo(R) CR Tablet Formulation
11. QRxPharma Receives Positive Feedback from Scientific Advice Meetings in Europe on MoxDuo®IR Development and Registration
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/28/2015)... MOUNTAIN VIEW, Calif. , May 28, 2015 ... healthcare informatics market, Frost & Sullivan recognizes ... Frost & Sullivan Award for Company of the ... effort to take HCM to the next level ... highly strategic acquisitions and followed them up with ...
(Date:5/28/2015)... -- Cardinal Health today announced that its March 1, 2015 ... for $1.944 billion in cash was formally accepted.  The ... and trade unions. The transaction is expected to close ... key non-U.S. countries towards the end of 2015, subject ... Headquartered in Fremont, Calif. , ...
(Date:5/28/2015)... SAN DIEGO , May 28, 2015 /PRNewswire/ ... of cell-free molecular diagnostics, announced today the launch ... Campaign for its Precision Cancer Monitoring SM ... Oncology Annual Meeting. The campaign will center on ... can gain hands on clinical experience with the ...
Breaking Medicine Technology:Frost & Sullivan Acknowledges Lexmark Healthcare's Energy, Creativity, and Diligence in Developing the Leading Next-Generation Healthcare Content Management Platform 2Frost & Sullivan Acknowledges Lexmark Healthcare's Energy, Creativity, and Diligence in Developing the Leading Next-Generation Healthcare Content Management Platform 3Frost & Sullivan Acknowledges Lexmark Healthcare's Energy, Creativity, and Diligence in Developing the Leading Next-Generation Healthcare Content Management Platform 4Frost & Sullivan Acknowledges Lexmark Healthcare's Energy, Creativity, and Diligence in Developing the Leading Next-Generation Healthcare Content Management Platform 5Cardinal Health Binding Offer To Acquire Cordis Accepted 2Cardinal Health Binding Offer To Acquire Cordis Accepted 3Cardinal Health Binding Offer To Acquire Cordis Accepted 4Trovagene Launches Commercial Marketing Campaign at the 2015 American Society of Clinical Oncology Annual Meeting 2Trovagene Launches Commercial Marketing Campaign at the 2015 American Society of Clinical Oncology Annual Meeting 3Trovagene Launches Commercial Marketing Campaign at the 2015 American Society of Clinical Oncology Annual Meeting 4
... Boston Scientific Corporation (NYSE: BSX ) ... quality of life outcomes, based on one-year data from ... while the overall cost effectiveness of percutaneous coronary intervention ... according to patient characteristics, PCI was more cost effective ...
... to be presented at Israel Society of ... reach 5 months from single treatment - Data ... scores of expensive injections MISGAV, Israel and LONDON, March ... that the latest, encouraging results of the Company,s ongoing ...
Cached Medicine Technology:SYNTAX Analysis Finds Treatment With TAXUS(R) Express2(TM) Stents More Cost Effective Than Bypass Surgery in Many Patients With Complex Coronary Artery Disease 2SYNTAX Analysis Finds Treatment With TAXUS(R) Express2(TM) Stents More Cost Effective Than Bypass Surgery in Many Patients With Complex Coronary Artery Disease 3SYNTAX Analysis Finds Treatment With TAXUS(R) Express2(TM) Stents More Cost Effective Than Bypass Surgery in Many Patients With Complex Coronary Artery Disease 4SYNTAX Analysis Finds Treatment With TAXUS(R) Express2(TM) Stents More Cost Effective Than Bypass Surgery in Many Patients With Complex Coronary Artery Disease 5Medgenics' Phase I/II Clinical Trial Now Shows EPODURE Continuous Anemia Treatment Lasting 5 Months in Kidney Disease Patients 2Medgenics' Phase I/II Clinical Trial Now Shows EPODURE Continuous Anemia Treatment Lasting 5 Months in Kidney Disease Patients 3Medgenics' Phase I/II Clinical Trial Now Shows EPODURE Continuous Anemia Treatment Lasting 5 Months in Kidney Disease Patients 4
(Date:5/28/2015)... (PRWEB) May 28, 2015 The Khanna ... interactive keratoconus web application to make learning about ... in the last few years. This proliferation of treatment ... are not aware of the nuances of the cutting ... Institute, realized that websites can be boring and printed ...
(Date:5/28/2015)... May 28, 2015 Sexual Health ... that advances sexual health and wellbeing in the ... of San Francisco (USF) will be the first ... assault recording and reporting system. , Callisto ... and confidential reporting experience for college sexual assault ...
(Date:5/28/2015)... (PRWEB) May 28, 2015 Optimity ... and implementing innovative models of care for healthcare ... support alternative reimbursements and help operationalize contracting and ... also unveils a bi-weekly series of seven “ ... Outcomes Based Contracting. Optimity is a strategy, operations ...
(Date:5/28/2015)... Cancer survivors who participated in the ... activity, fitness and quality of life, according to research ... and Jennifer Ligibel, MD, senior physician in the Susan ... Institute. The findings will be presented at this year’s ... Meeting in Chicago. , The study, designed ...
(Date:5/28/2015)... 28, 2015 The drug epidemic has struck ... article published on May 12th, 2015, by Bradenton , ... of time. The first victim, Dylan Besser (21) was a ... the scene. The second overdose victim, Julian Toomsen-Hall (18) was ... the alarming overdose deaths on campus, the college has created ...
Breaking Medicine News(10 mins):Health News:Dr.Khanna Announced the Release of an Interactive Web Application for Keratoconus Treatment 2Health News:University of San Francisco Becomes First in the Nation to Adopt College Sexual Assault Reporting System 2Health News:University of San Francisco Becomes First in the Nation to Adopt College Sexual Assault Reporting System 3Health News:Optimity Advisors Now Offers Outcomes Based Contracting Services to Support Engagement Model For New Healthcare Innovative Models of Care 2Health News:LIVESTRONG at the YMCA Program Shows Significant Gains for Cancer Survivor Participants 2Health News:LIVESTRONG at the YMCA Program Shows Significant Gains for Cancer Survivor Participants 3Health News:LIVESTRONG at the YMCA Program Shows Significant Gains for Cancer Survivor Participants 4Health News:Two College Campus Deaths Force Sarasota College to Create Drug Task Force 2Health News:Two College Campus Deaths Force Sarasota College to Create Drug Task Force 3
... national study of escalator-related injuries to older adults, researchers ... Dr.PH., MPH, of the Indiana University School of Medicine, ... from 1991 to 2005. The results of the study ... journal Accident Analysis and Prevention. , Using U.S. Consumer ...
... FALL RIVER, Mass., March 13 Millstone ... signed agreements,with four companies to provide loaner ... facility, which opened in October 2007.,Two of ... Innovative Spinal Technologies, Inc. and OMNI life ...
... to Ease the Process for Physicians to Select Electronic ... Ohio State,Medical Association (OSMA) announced that it is launching ... its kind, to help reduce the risk for,physicians who ... for,their practices., The Standards of Excellence Program, which ...
... on Restorative Options, HARRISBURG, Pa., March 13 ... PDA member dentists use a recently,published brochure by ... with patients., "The Pennsylvania Dental Association encourages ... oral health issues," said Dr. Jon J.,Johnston, President ...
... study at the University of Texas Medical Branch at ... most common diseases of young children: colds and ear ... 15 issue of Clinical Infectious Disease, confirmed the suspected ... young children, viral colds and ear infections. It also ...
... Mich. A commonly used medication that prevents blood ... damaging delicate vein walls and may accelerate healing ... new research from the University of Michigan Cardiovascular Center. ... more evidence to support the aggressive anti-clot efforts now ...
Cached Medicine News:Health News:Rate of escalator injuries to older adults has doubled 2Health News:Customers Take Advantage of Loaner Kit Processing Services at Millstone Medical Outsourcing's Memphis Facility 2Health News:Customers Take Advantage of Loaner Kit Processing Services at Millstone Medical Outsourcing's Memphis Facility 3Health News:OSMA Launches EMR Standards of Excellence Program 2Health News:OSMA Launches EMR Standards of Excellence Program 3Health News:OSMA Launches EMR Standards of Excellence Program 4Health News:OSMA Launches EMR Standards of Excellence Program 5Health News:Pennsylvania Dental Association Urges Members to Use New ADA Educational Material 2Health News:Researchers confirm link between common cold and ear infection 2Health News:Damaged veins heal faster with heparin treatment, laboratory study finds 2Health News:Damaged veins heal faster with heparin treatment, laboratory study finds 3Health News:Damaged veins heal faster with heparin treatment, laboratory study finds 4
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: